Close Menu
Home » Gene Editing Startup Beam Therapeutics Launches With $87M in Series A Funds

Gene Editing Startup Beam Therapeutics Launches With $87M in Series A Funds

May 17, 2018
|
staff reporter

NEW YORK (GenomeWeb) – Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome.

The funding round was led by F-Prime Capital Partners and ARCH Venture Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Ways to Make the Move

A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.

Fire at Russian Pathogen Lab

A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.

Proteins From the Past

Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.

PNAS Studies Look at Diabetes Susceptibility, S. Aureus Subpopulations, More

In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.

What's Popular?

In Business News

  1. 10x Genomics CEO Says Firm 'Ready for Growth' Following $357.5M IPO

    Premium

  2. LunaPBC Partners With Medfusion to Integrate EHR, Genomic Data-Sharing Platform

  3. Aethlon Medical Lands $1.9M SBIR Grant for Exosome Isolation Device

  4. Fulgent Genetics Taps PWNHealth to Oversee New Tests Marketed to Consumers

  5. Alzheimer's Disease Test Firm DiamiR Awarded Additional $345K From NIA

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.